Home » Topics » BioWorld Science

BioWorld Science
RSS

Genmab and Immatics partner on next-generation bispecific cancer immunotherapies

July 12, 2018

New phase II trial explores voclosporin ophthalmic solution for dry eye syndrome

July 12, 2018

Pivotal study of KP-415 in children with ADHD meets primary efficacy endpoint

July 12, 2018

Galapagos, AbbVie discover CFTR modulators

July 12, 2018

National Center for Global Health and Medicine, Kumamoto University and Yamasa patent antivirals

July 12, 2018

Amgen describes new beta-secretase inhibitors

July 12, 2018

OG-716, a lantibiotic that is active against Clostridium difficile infections

July 12, 2018

Argenx presents phase II data for ARGX-113 in myasthenia gravis

July 12, 2018

Advaxis withdraws conditional MAA for axalimogene filolisbac, advances ADXS-HOT program

July 12, 2018

Recursion set to begin phase I study of AI/ML-based drug candidate, REC-994

July 12, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.